NorthWest Biotherapeutics Inc (NWBO)

[bullrider2]

The K report stated DCVax-L is near completion. Enrollment for the 348 newly diagnose patients with brain cancer started over several years ago, and the patient enrollment was halted (stop) last year. The P3 clinical trial study went on with the 300 plus patients that was enrolled before the patient enrollment stopped. The question is at the end of P3 clinical trial study, how many Patients who was enrolled in the P3 clinical trial will survive when given DCVax-L for Brain Cancer and how long did the other patients lived after medicated with DCVax-L.

At the completion of DCVax-L P3 clinical trial will it be called a therapeutic treatment drug for a longer life span for patients who were diagnose with brain cancer, Or will it be called a immune vaccine for brain cancer.